Loading...
Loading...
Seattle Genetics, Inc.
SGEN announced today that ADCETRIS
(brentuximab vedotin) has been granted orphan drug designation by the U.S.
Food and Drug Administration (FDA) for the treatment of mycosis fungoides
(MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL). Seattle
Genetics and its ADCETRIS collaborator, Millennium: The Takeda Oncology
Company, are conducting the ALCANZA trial, a phase III clinical trial of
ADCETRIS for patients with CD30-positive relapsed CTCL, including MF. ADCETRIS
is not approved for the treatment of CTCL.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in